Literature DB >> 16579972

The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis.

Kyung-Hyun Kim1, Hyun-Chul Kim, Mee-Yul Hwang, Hoon-Kyu Oh, Tae-Sung Lee, Young-Chae Chang, Ho-Jung Song, Nam-Hee Won, Kwan-Kyu Park.   

Abstract

Liver fibrosis results from chronic damage to the liver by chronic hepatitis, alcohol, and toxic agents. A characteristic of liver fibrosis is an accumulation of extracellular matrix (ECM) protein, which distorts the hepatic architecture by forming a fibrous scar, and the subsequent development of regenerating nodules defines cirrhosis. Transforming growth factor (TGF)-beta1, one of the most powerful profibrogenic mediators, plays a major role in the development of liver cirrhosis and regulates ECM gene expression and matrix degradation. This study elucidates the changes of TGF-beta1-mediated signals during liver fibrogenesis by using RNA interference. In this experiment, the TGF-beta1 siRNAs reduced the expression of TGF-beta1 in the livers of CCl(4) injection compared with those of control group, and the expression of type I collagen and alpha-smooth muscle actin was decreased. In conclusion, this study demonstrates that TGF-beta1 siRNAs inhibit TGF-beta1 expression in the murine model of liver cirrhosis and might be a good therapeutic strategy to prevent liver cirrhosis in human.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16579972     DOI: 10.1016/j.bbrc.2006.03.087

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation.

Authors:  Hironobu Takahashi; Yuwei Wang; David W Grainger
Journal:  J Control Release       Date:  2010-08-19       Impact factor: 9.776

Review 2.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

3.  GFAP promoter-driven RNA interference on TGF-β1 to treat liver fibrosis.

Authors:  Ningning Yang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-02-23       Impact factor: 4.200

Review 4.  siRNA- and miRNA-based therapeutics for liver fibrosis.

Authors:  Zhen Zhao; Chien-Yu Lin; Kun Cheng
Journal:  Transl Res       Date:  2019-08-13       Impact factor: 7.012

5.  Preliminary experimental study of urethral reconstruction with tissue engineering and RNA interference techniques.

Authors:  Chao Li; Yue-Min Xu; Hong-Bin Li
Journal:  Asian J Androl       Date:  2013-04-01       Impact factor: 3.285

Review 6.  Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are?

Authors:  Kyung-Hyun Kim; Kwan-Kyu Park
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 7.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

8.  TGF-beta1 gene silencing for treating liver fibrosis.

Authors:  Kun Cheng; Ningning Yang; Ram I Mahato
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

9.  Hepatic stellate cell-specific gene silencing induced by an artificial microRNA for antifibrosis in vitro.

Authors:  Ying Chang; Hua-jun Jiang; Xue-mei Sun; Xiao-kun Cai; Xing-xing He; Pei-yuan Li; Wang-xian Tang; Yu-hu Song; Ju-sheng Lin
Journal:  Dig Dis Sci       Date:  2009-11-05       Impact factor: 3.199

Review 10.  Targeting transforming growth factor-beta signaling.

Authors:  Michael Pennison; Boris Pasche
Journal:  Curr Opin Oncol       Date:  2007-11       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.